Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.61 |
| ▸ | MAOA | P21397 | 6/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070556 | 0.87 | MAOB (0.55) | MAOBMAOA | |
| SCHEMBL19236097 | 0.86 | MAOB (0.63) | MAOBMAOASCN9APARP10NR4A2 | |
| SCHEMBL9129876 | 0.81 | MAOB (0.71) | MAOBMAOASCN9APARP10NR4A2 | |
| SCHEMBL7396562 | 0.81 | MAOB (0.71) | MAOBMAOASCN9APARP10NR4A2 | |
| SCHEMBL2185724 | 0.80 | SCN9A (0.57) | MAOBSCN9APARP10 | |
| SCHEMBL965829 | 0.78 | MAOB (0.70) | MAOBMAOASCN9APARP10 | |
| SCHEMBL1534880 | 0.78 | MAOB (0.69) | MAOBMAOASCN9APARP10NR4A2 | |
| SCHEMBL5228909 | 0.76 | ALDH1A1 (0.41) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL69350 | 0.75 | MAOB (1.00) | MAOBMAOASCN9A | |
| SCHEMBL2185703 | 0.75 | MAOB (0.53) | MAOBMAOASCN9ANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | disclosed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | disclosed |
| EP-2029130-A2 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | disclosed |
| EP-1870097-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007144153-A2 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-21 | — | — | WO | disclosed |